While Retatrutide wins on paper, Zepbound wins in the real world for a few key reasons: *The options weve highlighted as the winner are based on the evidence currently available
In this study, GLP-1 receptor agonist therapy correlated with a lower incidence of severe liver events compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (16.9 vs
However, metabolic disorders are fundamentally systemic diseases driven by impaired endocrine crosstalk (Theurey and Rieusset, 2017
This finding highlights the need for further research to understand the mechanisms through which these medications influence mental health and to identify which patient populations might benefit the most from each treatment, Guo said
Marx N, Federici M, Schtt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Furthermore, the human subject trials varied in length and dose, which makes it hard to conclude that GLP-1 use prevents muscle loss while losing fat at this time, and we dont know if exercise was a variable controlled for
